Bachem signs large volume contracts for peptides
Two contracts signed with order volumes of CHF 25 million in 2023 and CHF 150 million in 2024. Potential for significantly larger orders for the following years under negotiation. Companies agree to maintain customer confidentiality. Bachem Group (SIX: BANB) today...
Bachem with slight decline in sales to CHF 234.9 million in the first half of 2022. Strong growth expected in the second half of the year.
Group sales at CHF CHF 234.9 million at half year (-1.8% compared to prior-year period). EBITDA of CHF 67.3 million (-10.8% compared to prior-year period) with a margin of 28.7%. EBIT of CHF 51.6 million (-16.8% compared to prior-year period) with a margin of 22.0%....
Entering strategic collaboration with Lilly to manufacture oligo-based drug substances
Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
Bachem achieves sales of half a billion Swiss francs
Group sales increase to CHF 503.2 million, up 25.2% year-on-year. EBITDA increases from CHF 122.6 million to CHF 157.4 million with a margin of 31.3%. Operating income EBIT increases from CHF 96.7 million to CHF 128.9 million with a margin of 25.6%. Net income...